Quick Answer
Oric Pharmaceuticals, Inc. reported Operating Income of -$143.00 million for fiscal year 2025.
Oric Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$143.00M | -0.1% |
| 2024 | -$142.90M | -29.0% |
| 2023 | -$110.78M | -20.7% |
| 2022 | -$91.77M | -16.4% |
| 2021 | -$78.87M | -6.3% |
| 2020 | -$74.19M | -159.7% |
| 2019 | -$28.57M | -27.7% |
| 2018 | -$22.37M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$36.67M | +4.3% | +6.1% |
| June 30, 2025 | -$39.06M | -8.5% | -19.4% |
| March 31, 2025 | -$32.72M | -12.9% | +14.6% |
| September 30, 2024 | -$38.32M | -33.6% | -6.4% |
| June 30, 2024 | -$36.02M | -44.1% | -24.2% |
| March 31, 2024 | -$28.99M | -12.9% | -1.1% |
| September 30, 2023 | -$28.68M | -11.6% | -14.8% |
| June 30, 2023 | -$24.99M | -20.8% | +2.7% |
- Oric Pharmaceuticals, Inc. showed a decrease of -0.1% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Oric Pharmaceuticals, Inc.’s operating income has declined by 539.2% (from -$22.37 million to -$143.00 million).
- The most recent figure is from Oric Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: